Jamema Swamidas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jamema Swamidas has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
Umesh Mahantshetty
Homi Bhabha Cancer Hospital & Research Centre, Visakhapatnam, India
8 shared publicationsDeepak D. Deshpande
Department of Medical Physics, Tata Memorial Hospital, Mumbai, India
4 shared publications- Kari Tanderup
Danish Center for Particle Therapy, Aarhus University Hospital, 8200 N Aarhus, Denmark
4 shared publications Shyam K. Shrivastava
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India
4 shared publications- Alexis Dimitriadis
International Atomic Energy Agency, Department of Nuclear Sciences and Applications, Division of Human Health, Vienna, Austria
3 shared publications Dd Deshpande
Department of Medical Physics, Tata Memorial Hospital, Mumbai, India
3 shared publications
Latest Publications
- 22 January 2026
- Published by Springer Nature
- p. 141-168
Luminescence Dosimeters and Alanine
- Open Access
- 2 November 2024
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 32, 100665
Development and international multicentre pilot testing of a postal dosimetry audit methodology for high dose rate brachytherapy
- 2 November 2024
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 32, 100665
Open AccessDevelopment and international multicentre pilot testing of a postal dosimetry audit methodology for high dose rate brachytherapy
- Open Access
- 23 October 2024
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 32, 100657
Monte Carlo simulated correction factors for high dose rate brachytherapy postal dosimetry audit methodology
- 23 October 2024
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 32, 100657
Open AccessMonte Carlo simulated correction factors for high dose rate brachytherapy postal dosimetry audit methodology
- Open Access
- 3 May 2024
- Published by Wiley in Medical Physics
- Vol. 51 (8) , 5632-5644
The IAEA remote audit of small field dosimetry for testing the implementation of the TRS‐483 code of practice
Background: The TRS‑483, an IAEA/AAPM International Code of Practice on dosimetry of small static photon fields, underwent testing via an IAEA coordinated research project (CRP). Alongside small field output factors (OFs) measurements using active dosimeters by CRP participants, the IAEA Dosimetry Laboratory received a mandate to formulate a remote small field dosimetry audit method using its passive dosimetry systems.Purpose: This work aimed to develop a small field dosimetry audit methodology employing radiophotoluminescent dosimeters (RPLDs) and radiochromic films. The methodology was subsequently evaluated through a multicenter pilot study with CRP participants.Methods: The developments included designing and manufacturing a dosimeter holder set and the characterization of an RPLD system for measurements in small photon fields using the new holder. The audit included verification of small field OFs and lateral beam profiles for small fields. At first, treatment planning system (TPS) calculated OFs were checked against a reference data set that was available for conventional linacs. Second, calculated OFs were verified through the RPLD measurement of point doses in a machine‐specific reference field, 4 cm × 4 cm, 2 cm × 2 cm, and 1 cm × 1 cm, corresponding size circular fields or nearest achievable field sizes. Lastly, profile checks in in‐plane and cross‐plane directions were done for the two smallest fields by comparing film measurements with TPS calculations at 20%, 50%, and 80% isodose levels.Results: RPLD correction factors for small field measurements were approximately unity. However, they influenced the dose determination's overall uncertainty in small fields, estimated at 2.30% (k = 1 level). Considering the previous experience in auditing reference beam output following the TRS‐398 Code of Practice, the acceptance limit of 5% for the ratio of the dose determined by RPLD to the dose calculated by TPS, DRPLD/DTPS, was considered adequate. The multicenter pilot study included 15 participants from 14 countries (39 beams). Consistent with the previous findings, the results of the OF check against the reference data confirmed that TPSs tend to overestimate OFs for the smallest fields included in this exercise. All except three RPLD measurement results were within the acceptance limit, and the spread of results increased for smaller field sizes. The differences between the film measured and TPS calculated dose profiles were within 3 mm for most of the beams checked; deviated results revealed problems with TPS commissioning and calibration of the treatment unit collimation systems.Conclusion: The newly developed small field dosimetry audit methodology proved effective and successfully complemented the CRP OF measurements by participants with RPLD audit results.
- 3 May 2024
- Published by Wiley in Medical Physics
- Vol. 51 (8) , 5632-5644
Open AccessThe IAEA remote audit of small field dosimetry for testing the implementation of the TRS‐483 code of practice
Background: The TRS‑483, an IAEA/AAPM International Code of Practice on dosimetry of small static photon fields, underwent testing via an IAEA coordinated research project (CRP). Alongside small field output factors (OFs) measurements using active dosimeters by CRP participants, the IAEA Dosimetry Laboratory received a mandate to formulate a remote small field dosimetry audit method using its passive dosimetry systems.Purpose: This work aimed to develop a small field dosimetry audit methodology employing radiophotoluminescent dosimeters (RPLDs) and radiochromic films. The methodology was subsequently evaluated through a multicenter pilot study with CRP participants.Methods: The developments included designing and manufacturing a dosimeter holder set and the characterization of an RPLD system for measurements in small photon fields using the new holder. The audit included verification of small field OFs and lateral beam profiles for small fields. At first, treatment planning system (TPS) calculated OFs were checked against a reference data set that was available for conventional linacs. Second, calculated OFs were verified through the RPLD measurement of point doses in a machine‐specific reference field, 4 cm × 4 cm, 2 cm × 2 cm, and 1 cm × 1 cm, corresponding size circular fields or nearest achievable field sizes. Lastly, profile checks in in‐plane and cross‐plane directions were done for the two smallest fields by comparing film measurements with TPS calculations at 20%, 50%, and 80% isodose levels.Results: RPLD correction factors for small field measurements were approximately unity. However, they influenced the dose determination's overall uncertainty in small fields, estimated at 2.30% (k = 1 level). Considering the previous experience in auditing reference beam output following the TRS‐398 Code of Practice, the acceptance limit of 5% for the ratio of the dose determined by RPLD to the dose calculated by TPS, DRPLD/DTPS, was considered adequate. The multicenter pilot study included 15 participants from 14 countries (39 beams). Consistent with the previous findings, the results of the OF check against the reference data confirmed that TPSs tend to overestimate OFs for the smallest fields included in this exercise. All except three RPLD measurement results were within the acceptance limit, and the spread of results increased for smaller field sizes. The differences between the film measured and TPS calculated dose profiles were within 3 mm for most of the beams checked; deviated results revealed problems with TPS commissioning and calibration of the treatment unit collimation systems.Conclusion: The newly developed small field dosimetry audit methodology proved effective and successfully complemented the CRP OF measurements by participants with RPLD audit results.
- 5 March 2023
- Published by Elsevier in Brachytherapy
- Vol. 22 (3) , 325-333
Sigmoid dose accumulation and reporting for multifractionated brachytherapy for cervical cancer: Methodological development of sigmoid points through virtual endoscopic method
- 5 March 2023
- Published by Elsevier in Brachytherapy
- Vol. 22 (3) , 325-333
Sigmoid dose accumulation and reporting for multifractionated brachytherapy for cervical cancer: Methodological development of sigmoid points through virtual endoscopic method
- Open Access
- 1 December 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 153, 114-121
Phantom-based quality assurance for multicenter quantitative MRI in locally advanced cervical cancer
- 1 December 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 153, 114-121
Open AccessPhantom-based quality assurance for multicenter quantitative MRI in locally advanced cervical cancer
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , S1-S2
Phase III Randomized Trial of Postoperative Adjuvant Conventional Radiation (3DCRT) versus Image Guided Intensity Modulated Radiotherapy (IG-IMRT) in Cervical Cancer (PARCER): Final Analysis
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , S1-S2
Phase III Randomized Trial of Postoperative Adjuvant Conventional Radiation (3DCRT) versus Image Guided Intensity Modulated Radiotherapy (IG-IMRT) in Cervical Cancer (PARCER): Final Analysis
- 1 February 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 143, 1-11
Image registration, contour propagation and dose accumulation of external beam and brachytherapy in gynecological radiotherapy
- 1 February 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 143, 1-11
Image registration, contour propagation and dose accumulation of external beam and brachytherapy in gynecological radiotherapy
- 18 July 2019
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 92 (1101) , 20181053
Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit
Objectives: To evaluate the outcomes of stereotactic radiotherapy (SBRT) in the treatment of inoperable hepatocellular carcinomas (HCC) that are unsuitable for, or refractory to other liver-directed therapies. Methods: Between March 2015 and June 2018, patients with primary HCCs refractory to or unsuitable for treatment with other liver-directed therapies were treated with SBRT. Patients of Child status A5-B7 and with normal liver reserve ≥ 700 cc were preferred. Local control (LC), overall survival (OS), progression free survival (PFS) and effect of prognostic factors were analysed. Results: 21 patients with inoperable HCCs were treated. The median tumour diameter was 9.6 cm (5-21) and median tumour volume was 350 cc (32.9 – 2541). The median SBRT dose prescription was 42 Gy/6 fractions (25 – 54 Gy/6#). The 1- and 2-year LC rate was 88 and 43 % respectively. Overall rate of > grade III toxicity was 14 %. Patients with Child A5 liver function had a better median OS than A6 and B7 patients [21 vs 11 vs 8 months]. Also, tumours with GTV < 350 cc volumes had a better OS compared to GTV of greater than 350 cc [24 months vs 8 months, p value = 0.004]. Conclusions: This study showed that SBRT can be used safely and effectively to treat inoperable HCCs with or without prior loco-regional therapies, resulting in good local control and survival with acceptable toxicity. Advances in knowledge: Use of SBRT in inoperable HCC is safe and effective.
- 18 July 2019
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 92 (1101) , 20181053
Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit
Objectives: To evaluate the outcomes of stereotactic radiotherapy (SBRT) in the treatment of inoperable hepatocellular carcinomas (HCC) that are unsuitable for, or refractory to other liver-directed therapies. Methods: Between March 2015 and June 2018, patients with primary HCCs refractory to or unsuitable for treatment with other liver-directed therapies were treated with SBRT. Patients of Child status A5-B7 and with normal liver reserve ≥ 700 cc were preferred. Local control (LC), overall survival (OS), progression free survival (PFS) and effect of prognostic factors were analysed. Results: 21 patients with inoperable HCCs were treated. The median tumour diameter was 9.6 cm (5-21) and median tumour volume was 350 cc (32.9 – 2541). The median SBRT dose prescription was 42 Gy/6 fractions (25 – 54 Gy/6#). The 1- and 2-year LC rate was 88 and 43 % respectively. Overall rate of > grade III toxicity was 14 %. Patients with Child A5 liver function had a better median OS than A6 and B7 patients [21 vs 11 vs 8 months]. Also, tumours with GTV < 350 cc volumes had a better OS compared to GTV of greater than 350 cc [24 months vs 8 months, p value = 0.004]. Conclusions: This study showed that SBRT can be used safely and effectively to treat inoperable HCCs with or without prior loco-regional therapies, resulting in good local control and survival with acceptable toxicity. Advances in knowledge: Use of SBRT in inoperable HCC is safe and effective.